Mytocel MSKUnited Kingdom
Gloved hands attaching a syringe to the single-use Rigeneracons RS device

Technology

From auricular cartilage to an injectable micrograft suspension.

Mytocel MSK® is built on Rigenera® technology and the AMT® (Autologous Micrografting Technology) platform.

Request UK pricingSee the procedure

What is in the suspension

Cells, pericytes and matrix from the patient’s own cartilage.

Characterisation studies describe a heterogeneous suspension of cartilage-derived cells (chondrocytes and progenitor cells), pericytes and extracellular-matrix components from the donor tissue.1

A syringe held in a gloved hand with a bead of the prepared suspension at the tip
The prepared suspension, illustrative
Chondrocytes and progenitor cells
Cartilage-derived cells from the donor tissue, as described in the characterisation studies.1
Pericytes
Carried from the donor tissue alongside the cartilage-derived cells, as described in the characterisation studies.1
Extracellular-matrix components
Matrix components from the donor tissue, collected in the same heterogeneous suspension as the cells.1
Stylised illustration of cells suspended in fluid, representing the cellular content of the micrograft suspension.
Cellular and extracellular-matrix components carried in the suspension, illustrative

Processing

Mechanical, not biological.

Mechanical disaggregation only: no laboratory expansion, no enzymatic digestion, no culture step.

Micrografts are collected through a calibrated 80 µm filter, the size range associated with viable progenitor-rich fractions in the characterisation work.1

Unlike cultured chondrocyte implantation, there is no laboratory expansion and no second procedure.

Explainer plate showing what is in the micrograft solution: auricular cartilage, gentle mechanical preparation, and an autologous suspension of progenitor cells, chondrocytes, pericytes and extracellular matrix.
Illustrative representation of the mechanical path from auricular cartilage to suspension
A description of the processes, not a comparison of outcomes.
Mytocel MSKCultured chondrocyte implantation
Laboratory cultureNoneLaboratory expansion
Number of proceduresOne sessionTwo procedures
Tissue sourcePatient’s own auricular cartilagePatient’s own cartilage, expanded in a laboratory

System components

Rigeneracons RS and the N4SA processing unit.

A studio render of the processing unit, a single-use cartridge and its cap on a white background
Illustrative render of the system
Rigenera N4SA processing unit
Rigeneracons RS single-use disaggregation device
Class IIaSingle use

Rigeneracons RS

Disaggregation device

Rigeneracons® RS: sterile, single-use Class IIa medical device, designed to mechanically disaggregate the auricular cartilage sample and collect the micrograft suspension through the calibrated 80 µm filter.

Class IReusable

Rigenera N4SA

Processing unit

Rigenera® N4SA: Class I motor-driven processing unit. The reusable unit provides the calibrated rotational impulse for the documented processing cycle.

Storage. Store at room temperature in a dry, ventilated place.

Regulatory status

Rigeneracons® RS: sterile, single-use Class IIa medical device. Rigenera® N4SA: Class I motor-driven processing unit. CE marked; accepted on the Great Britain market under current transitional arrangements. Registered with the MHRA.

Where the evidence sits

Mechanistic rationale, pre-clinical models, small clinical series.

Nine publications and two preliminary reports: a three-year follow-up series (n = 8), two prospective ten-patient studies to 6 and 12 months, preliminary clinical reports, pre-clinical models and mechanistic characterisation. No randomised controlled trial has been published.234

Read every study
A gloved hand holding the round disaggregation grid of the single-use device.
The disaggregation grid of the single-use device
Evidence pyramid, top to bottom: Randomised controlled trials (none published); Prospective clinical series (n = 8 to 10); Preliminary reports; Pre-clinical models; Mechanistic characterisation. Highlighted: Mechanistic characterisation.Randomised controlled trialsnone publishedProspective clinical seriesn = 8 to 10Preliminary reportsPre-clinical modelsMechanistic characterisation

References

  1. 1.Viganò M, Tessaro I, Trovato L, et al. Rationale and pre-clinical evidence for autologous cartilage micrografts in cartilage repair. 2018. View source
  2. 2.Marcarelli M, Zappia M, Rissolio L, et al. Cartilage micrografts as a novel non-invasive and non-arthroscopic autograft procedure for knee chondropathy: three-year follow-up. J Clin Med. 2021;10(2):322. View source
  3. 3.Tsoukas D, Muntean I, Simos C, Sabido-Vera R. Prospective observational study of a non-arthroscopic autologous cartilage micrografting technology for knee osteoarthritis. Bioengineering. 2023;10(11):1294. View source
  4. 4.Helito CP, Pessei V, Zaniboni C, Muntean I, et al. Efficacy of autologous micrografting technology in managing osteoarthritis pain: a pilot study. Bioengineering. 2024;11(11):1119. View source

Bring Mytocel MSK to your clinic.

UK stock, protocol training, first-case support and structured outcome collection, from the exclusive UK supplier.

Request UK pricingArrange an introduction